Imugene Limited
IUGNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $4 | $5 | $12 | $13 |
| % Growth | -11.5% | -57.8% | -9.2% | – |
| Cost of Goods Sold | $0 | $6 | $2 | $2 |
| Gross Profit | $4 | $5 | $10 | $11 |
| % Margin | 100% | 100% | 81.3% | 81.4% |
| R&D Expenses | $47 | $87 | $31 | $37 |
| G&A Expenses | $28 | $60 | $18 | $12 |
| SG&A Expenses | $28 | $60 | $18 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $1 | $0 |
| Other Operating Expenses | $1 | $12 | $2 | $2 |
| Operating Expenses | $75 | $159 | $51 | $51 |
| Operating Income | -$71 | -$154 | -$40 | -$38 |
| % Margin | -1,613.5% | -3,092.9% | -337.6% | -292.5% |
| Other Income/Exp. Net | $2 | -$1 | $2 | $0 |
| Pre-Tax Income | -$69 | -$154 | -$38 | -$38 |
| Tax Expense | $0 | -$5 | -$12 | -$13 |
| Net Income | -$69 | -$150 | -$38 | -$38 |
| % Margin | -1,569.8% | -3,011.7% | -321.9% | -292% |
| EPS | -0.32 | -0.72 | -0.21 | -0.23 |
| % Growth | 55.6% | -242.9% | 8.7% | – |
| EPS Diluted | -0.32 | -0.72 | -0.21 | -0.23 |
| Weighted Avg Shares Out | 219 | 208 | 185 | 166 |
| Weighted Avg Shares Out Dil | 219 | 208 | 185 | 166 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $5 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $6 | $2 | $2 |
| EBITDA | -$67 | -$148 | -$47 | -$35 |
| % Margin | -1,533.5% | -2,977.4% | -402.7% | -272.1% |